Abstract: The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of Quillaja Saponaria Molina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 ?g. The present invention further provides an adjuvant composition in a human dose suitable volume comprising between 1 and 30 ?g of a lipopolysaccharide and between 1 and 30 ?g of an immunologically active saponin fraction presented in the form of a liposome.
Abstract: The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator.
Type:
Grant
Filed:
January 23, 2015
Date of Patent:
March 27, 2018
Assignee:
Forsyth Dental Infirmary for Children
Inventors:
Antonio Campos-Neto, Mark Cayabyab, Margaret Duncan
Abstract: The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator.
Type:
Grant
Filed:
June 3, 2016
Date of Patent:
February 6, 2018
Assignee:
Forsyth Dental Infirmary for Children
Inventors:
Antonio Campos-Neto, Mark Cayabyab, Margaret Duncan
Abstract: This disclosure describes methods and compositions that involve endogenous retrovirus proteins as diagnostic markers and/or therapeutic agents. The detection of endogenous retrovirus envelope proteins on a cell surface can indicate early neoplasticity of the cell. Antibody compositions that specifically bind to cell-surface-expressed endogenous retrovirus proteins may be used in such diagnostic methods. Overexpression of the endogenous retrovirus proteins can slow cell growth and decrease cell viability.
Abstract: The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.
Type:
Grant
Filed:
September 8, 2016
Date of Patent:
January 2, 2018
Assignee:
Celltrion Inc.
Inventors:
Shin Jae Chang, Ki Sung Kwon, Kye Sook Yi, Hyun Joo Lee, Jae Won Jeon, Hwang Keun Jun, Min Seok Chang
Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5A (PPV5A) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.
Type:
Grant
Filed:
May 15, 2015
Date of Patent:
December 5, 2017
Assignee:
Boehringer Ingelheim Vetmedica, Inc.
Inventors:
Arun V. Iyer, Dianna M. Murphy Jordan, Abby Rae Patterson, Michael B. Roof, Eric Martin Vaughn, Joseph Gilbert Victoria, Callie Ann Visek
Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5B (PPV5B) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.
Type:
Grant
Filed:
May 26, 2015
Date of Patent:
November 28, 2017
Assignee:
Boehringer Ingelheim Vetmedica, Inc.
Inventors:
Arun V. Iyer, Dianna M. Murphy Jordan, Abby Rae Patterson, Michael B. Roof, Eric Martin Vaughn, Joseph Gilbert Victoria, Callie Ann Visek
Abstract: Compared to an unadjuvanted vaccine, an adjuvanted influenza vaccine can reduce by almost a quarter the risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) in elderly recipients. Thus the invention provides a method for immunizing an elderly subject by administering an adjuvanted influenza vaccine, whereby the subject's risk of hospitalization for respiratory illness (e.g. influenza and pneumonia) is reduced relative to an elderly subject who receives an unadjuvanted influenza vaccine.
Abstract: Materials and methods for use of constrained cohydration agents in the purification of biological materials such as antibodies, viruses, cells, and cellular organelles in connection with convective chromatography, fluidized bed or co-precipitation applications.
Type:
Grant
Filed:
June 1, 2012
Date of Patent:
November 7, 2017
Assignee:
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against mycobacterial infections. The invention also relates to pharmaceutical compositions and methods for the prevention and treatment of mycobacterial infections. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing and treating infections in Mycobacterium tuberculosis.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
November 7, 2017
Assignee:
Université de Genève
Inventors:
Elodie Anne Françoise Belnoue, Stéphanie Gabrielle Darbre Abdelrahman, Arun Thomas Kamath, Paul Lambert, Claire-Anne Siegrist-Julliard, Daniel David Pinschewer
Abstract: This invention provides a method of attenuating porcine pseudorabies virus, which can effectively and reproducibly attenuate porcine pseudorabies virus. The attenuated strain of porcine pseudorabies virus by use of said method can provide effective immunization for pigs.
Abstract: This invention provides a method of attenuating porcine pseudorabies virus, which can effectively and reproducibly attenuate porcine pseudorabies virus. The attenuated strain of porcine pseudorabies virus by use of said method can provide effective immunization for pigs.
Abstract: The invention provides methods and means for distinguishing FECV and FIPV, and methods and means for determining whether FIPV is present in a sample. Further provided are primers and probes for detecting FIPV specific nucleic acid sequences encoding a spike protein, antibodies for detecting a FIPV, and an immunogenic composition and use thereof for eliciting an immune response against a feline coronavirus, preferably a FIPV.
Type:
Grant
Filed:
January 18, 2011
Date of Patent:
October 24, 2017
Assignee:
UNIVERSITEIT UTRECHT HOLDING B.V.
Inventors:
Petrus Josephus Marie Rottier, Hui-wen Chang, Herman F. Egberink
Abstract: Compositions and methods for treating immune cells and activating immune responses are disclosed. The compositions comprise one or more optically active chiral cationic lipids.
Type:
Grant
Filed:
April 14, 2009
Date of Patent:
October 17, 2017
Assignee:
PDS Biotechnology Corporation
Inventors:
Elizabeth Ann Vasievich, Weihsu Claire Chen, Kenya Toney Johnson, Gregory Conn, Frank Bedu-Addo, Leaf Huang
Abstract: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.
Abstract: The invention relates to a novel porcine circovirus type 2 (PCV2) strain. The invention also relates to immunogenic compositions containing the novel PCV2 strain, PCV2 test kits, and applications of the novel PCV2 strain.
Type:
Grant
Filed:
July 2, 2015
Date of Patent:
September 26, 2017
Assignee:
SBC VIRBAC LIMITED.
Inventors:
Tsun-Yung Kuo, Hsu-Chung Gabriel Chen, Chung-Chin Wu, Han-Ting Chen
Abstract: A host antigen-specific antibody testing system and method. The a ternary complex of the antigen, a ligand-bound anti-host IgM, and a non-host anti-antigen IgG detector conjugate selectively form a quaternary complex with host antibodies, wherein the host antibodies and IgG compete for the antigen, and the anti-host IgM binds the host antibodies. The quaternary complex is retained by an immobilized IgM ligand binding agent, and any residual ternary complex is retained by a later encountered immobilized anti-non-host IgG. If sufficient host antibodies have a high affinity for the antigen, the complex is detected at the quaternary complex detection region based on the presence of the detector, and if there are insufficient high affinity host antibodies, the ternary complex migrates past the quaternary complex detection region and is retained and detected at a control region.
Abstract: Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.